Status:
RECRUITING
Reduced MBF Regimen for Patients >=55 Years With Myeloid Malignancies
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Conditions:
Disease-free Survival
Eligibility:
All Genders
55-65 years
Phase:
PHASE2
Brief Summary
In this multiple-center phase II study, the aim is to evaluate the clinical outcome of reduced intensity conditioning regimen with fludarabine (150mg/m2), busulfan (6.4mg/kg) and melphalan (100mg/m2) ...
Detailed Description
Conditioning regimen with double alkylating agents such as busulfan + melphalan or Busulfan + thiotepa have been shown to improve the transplantation outcome in terms of lower relapse rate in various ...
Eligibility Criteria
Inclusion
- Age 55-65
- patients with HLA-matched sibling donors, 9-10/10 matched unrelated donors or haplo-identical donors.
- patients with AML in remission, or MDS in any stage, or CMML in any stage
- inform consent provided
Exclusion
- patients with abnormal liver (\>3N), renal (1.5N) or cardiac function
- patients with active infection
Key Trial Info
Start Date :
June 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT05436561
Start Date
June 1 2022
End Date
December 1 2025
Last Update
February 18 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Blood & Marrow Transplantation Center, RuiJin Hospital
Shanghai, Shanghai Municipality, China, 200025
2
Shanghai No 6 Hospital
Shanghai, China